An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review

Mehrizi, Tahereh Zadeh; Hosseini, Kamran Mousavi

doi:10.1039/d1na00119a

Cited by 11 publications

(7 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 Furthermore, Zadeh and Mousavi noted that PEGylated rFVIII had improved biocompatibility and circulation duration. 62 PEGylated factors such as damoctocog alfa pegol (BAY 94-9027) and BAX 855 have a reported half-life of about 1.5-fold that of the SHL rFVIII with improved PK profiles. For instance, Bayer's BAY 94-9027, a phase III clinical product, has a halflife of 19 hours.…”

Section: New Generations Of Recombinant Fviii With An Improved Safety...mentioning

confidence: 99%

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Chandran,

Tohit,

Stanslas

et al. 2024

Semin Thromb Hemost

View full text Add to dashboard Cite

The management of hemophilia A has undergone a remarkable revolution, in line with technological advancement. In the recent past, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis has become a key focus, as it can lead to improved health outcomes and reduced health care costs in the long term. Recent bioengineering research is directed toward prolonging the recombinant FVIII (rFVIII) coagulant activity and synthesising higher FVIII yields. As an outcome, B-domain deleted, polyethylene glycolated, single-chain, Fc-fused rFVIII, and rFVIIIFc-von Willebrand Factor-XTEN are available for patients. Moreover, emicizumab, a bispecific antibody, is commercially available, whereas fitusiran and tissue factor pathway inhibitor are in clinical trial stages as alternative strategies for patients with inhibitors. With these advancements, noninfectious complications, such as inhibitor development, allergic reactions, and thrombosis, are emerging concerns requiring careful management. In addition, the recent approval of gene therapy is a major milestone toward a permanent cure for hemophilia A. The vast array of treatment options at our disposal today empowers patients and providers alike, to tailor therapeutic regimens to the unique needs of each individual. Despite significant progress in modern treatment options, these highly effective therapies are markedly more expensive than conventional replacement therapy, limiting their access for patients in developing countries.

show abstract

Section: New Generations Of Recombinant Fviii With An Improved Safety...mentioning

confidence: 99%

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Chandran,

Tohit,

Stanslas

et al. 2024

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…NPs can also be used for the purpose of improved stability of coagulation factors, anticoagulant or procoagulant effects, or as drug carriers. Therefore, the interactions of NPs with the blood coagulation system have to be investigated (Ilinskaya and Dobrovolskaia, 2013 ; Mehrizi and Hosseini, 2021 ).…”

Section: Plasma Proteinsmentioning

confidence: 99%

“…Blood cells and plasma proteins are also damaged or lost in the process of eradicating contaminations (Klein 2005 ). Furthermore, current plasma protein purification processes are not efficient and cost-effective (Evtushenko et al 2005 ; Mehrizi and Hosseini 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…Nanotechnology as an advancing science has provided new opportunities for studying not only the mechanisms of cell damage but also the development of efficient and safe methods for storing cells outside the body which offers a potential solution to the challenges of blood products storage and separation (Belousov et al 2019 ; Dashti Rahmat Abadi et al 2014 ; Mehrizi 2021a ; Shahabi et al 2014 ; Zadeh Mehrizi 2021a , b , c ; Zadeh Mehrizi and Amini Kafiabad 2021a , b ; Zadeh Mehrizi et al 2021 ; Zadeh Mehrizi and Eshghi 2021 ; Zadeh Mehrizi and Mousavi Hosseini 2021 ). Carbon nanoparticles have received much attention due to their particular optical, thermal, mechanical, electrical, and chemical features.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011–2021

Mehrizi

Ardestani

2022

Prog Biomater

Self Cite

View full text Add to dashboard Cite

Despite the importance of the proper quality of blood products for safe transfusion, conventional methods for preparation and their preservation, they lack significant stability. Non-metal nanoparticles with particular features may overcome these challenges. This review study for the first time provided a comprehensive vision of the interaction of non-metal nanoparticles with each blood product (red blood cells, platelets and plasma proteins). The findings of this review on the most effective nanoparticle for improving the stability of RBCs indicate that graphene quantum dots and nanodiamonds show compatibility with RBCs. For increasing the stability of platelet products, silica nanoparticles exhibited a suppressive impact on platelet aggregation. Pristine graphene also shows compatibility with platelets. For better stability of plasma products, graphene oxide was indicated to preserve free human serum albumin from thermal shocks at low ionic strength. For increased stability of Factor VIII, mesoporous silica nanoparticles with large pores exhibit the superb quality of recovered proteins. Furthermore, 3.2 nm quantum dots exhibited anticoagulant effects. As the best promising nanoparticles for immunoglobulin stability, graphene quantum dots showed compatibility with γ-globulins. Overall, this review recommends further research on the mentioned nanoparticles as the most potential candidates for enhancing the stability and storage of blood components. Graphical abstract

show abstract

“…Some proteins and their hydrolysis products provide nutrition to the body while enhancing human immunity 10 . Some immunoglobulins, pro‐inflammatory cytokines, and organ indices were found to reflect the immune function status of mice 11‐14 . Therefore, using rinsed surimi (RS) and US to feed immunocompromised mice and observing the immune regulation ability of the mice during feeding can explain the difference in the effect of RS and US.…”

Section: Introductionmentioning

confidence: 99%

Unrinsed Nemipterus virgatus surimi provides more nutrients than rinsed surimi and helps recover immunosuppressed mice treated with cyclophosphamide

et al. 2023

View full text Add to dashboard Cite

BACKGROUND The rinsing process in the production of surimi can cause the loss of some important nutrients. To investigate the differences in nutritional properties between rinsed surimi (RS) and unrinsed surimi (US), this study compared the elemental composition, amino acid composition, fatty acid composition, proteomics, and an immunosuppression mouse model of surimi before and after rinsing, and analyzed the nutritional and immunological properties of RS and US. RESULTS The results showed that the protein, fat, and ash contents of RS were decreased compared with those of US; specifically, the contents of essential amino acids, semi‐essential amino acids, non‐essential amino acids, saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids were decreased. In the non‐labeled quantitative proteomics analysis, three high‐abundance quantifiable protein contents and 68 low‐abundance quantifiable protein contents were found in RS (P‐values < 0.05, ratio > 2). Immune function experiments in mice revealed that both RS and US contributed to the recovery of immunity in immunocompromised mice. The effect of US was better than that of RS. CONCLUSION The rinsing process in surimi processing leads to the loss of nutrients in surimi. US promotes the recovery of immunity in immunocompromised mice more effectively than RS. © 2023 Society of Chemical Industry.

show abstract

An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review

Abstract: FVIII and immunoglobulins (Igs) are the most prominent plasma proteins which play a vital role in plasma hemostasis. These proteins have been implemented frequently in protein therapy. So, their maintenance,...

Cited by 11 publications

References 112 publications

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011–2021

Unrinsed Nemipterus virgatus surimi provides more nutrients than rinsed surimi and helps recover immunosuppressed mice treated with cyclophosphamide

Contact Info

Product

Resources

About